NCT02665416 - Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 25, 2016

Primary Completion Date

October 30, 2019

Study Completion Date

October 30, 2019

Conditions

Advanced/Metastatic Solid Tumors

Interventions

DRUG

Selicrelumab

Selicrelumab will be provided as concentrate for solution to be administered via SC injection

DRUG

Vanucizumab

Vanucizumab will be provided as solution to be administered via IV infusion.

DRUG

Bevacizumab

Bevacizumab will be administered via IV infusion.

Trial Locations (16)

1200

Cliniques Universitaires St-Luc, Brussels

2100

Rigshospitalet; Onkologisk Klinik, København Ø

20132

Irccs Ospedale San Raffaele;Oncologia Medica, Milan

27514

University of North Carolina at Chapel Hill, Chapel Hill

28050

START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid

46010

Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia

80262

Univ of CO Health Science Ctr, Denver

90048

Cedars Sinai Medical Center, Los Angeles

06520

Yale Cancer Center; Medical Oncology, New Haven

02215

Dana Farber Cancer Institute, Boston

M5G 2M9

University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto

1066 CX

Antoni van Leeuwenhoek Ziekenhuis, Amsterdam

3015 GD

Erasmus Medisch Centrum, Rotterdam

08908

ICO L'Hospitalet; Servicio de oncologia medica, L'Hospitalet de Llobregat

08003

Hospital del Mar; Servicio de Oncologia, Barcelona

08035

Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY